Evidence boundary, checked 8 September 2026: a company-issued release dated 5 September 2026 and its current product page confirm one new Japanese 50 mL body oil built around a visible water-and-oil system that is shaken before use. This is a product-definition signal. It does not establish category growth, sales velocity, review growth, stock pressure or demand for a GUOCUI product.
For private-label buyers, the useful question is not whether to reproduce that item. It is whether a body-care brief can use controlled phase separation to make the preparation step visible while still delivering repeatable dispensing, preservation and a practical post-shower routine. That question creates a distinct dual-phase body serum OEM sourcing path.
Verified Facts, Factory-Side Inference and What Is Not Claimed
Verified facts: Churacos announced the ULRUB body oil on 5 September 2026. The company release identifies a 50 mL product with equal water and oil layers, and the current official page instructs the user to shake until the layers mix. Both pages were readable on 8 September. These facts belong to that company’s product.
Factory-side inference: a private-label version would need the water-containing phase, emollient phase, remix window, dispenser and filled package reviewed together. The most useful early work is a comparison of phase behaviour and packaging, followed by the evidence plan for the selected formula.
Not claimed: the official launch does not show retail sell-through, natural review velocity, multi-market adoption or a proven buyer order. GUOCUI has not adopted the reference formula, ratio, colour, scent, botanical story, bottle, artwork, images or claims. No finished test, MOQ, price, capacity or production timing is established by this brief.
Why This Is a Distinct Catalogue Question
GUOCUI already presents a dual-phase facial micro-mist, a bi-phase facial cream-lotion serum, uniform post-shower body serum-lotions and conventional body oils. Those pages cover different formula and use routes. A body serum-oil that separates at rest and is deliberately remixed before dispensing instead connects a body-use setting with phase control, water-phase preservation and repeat-dose review.
The overlap check matters because a new scent, colour or ingredient story would not justify another product page. The new direction is the filled-pack decision system: how the two phases return, redisperse and leave the package through repeated use. If that distinction cannot be maintained in samples, the buyer should choose an existing uniform body serum-lotion or single-phase body oil route.
Decision 1: Define the Job of Each Phase
Start with the desired body finish and use setting. The water-containing phase may support a lighter humectant-led feel, while the emollient phase may supply slip and a softer finish. Ingredient selection should follow the target market and evidence plan. Do not start from a copied percentage or branded botanical list.
A good brief describes the experience in observable terms: spread, tack, residue, fragrance level and the desired time in the post-shower routine. “More water” or “more oil” is not automatically better. The phase ratio becomes a controlled development variable rather than a headline borrowed from another product.
Decision 2: Set a Reproducible Shake and Return Protocol
Record how the bottle is stored, how the sample is shaken and what mixed appearance is expected before dispensing. Then observe how quickly the layers return and whether the pattern changes across repeated cycles. Look for sediment, persistent droplets, foam, colour shift and material around the neck or closure.
The protocol should use sample codes and consistent observations. A dramatic visual swirl is useful content only when it represents the actual approved sample. It cannot replace the stability and safety work selected for the formula.
Decision 3: Measure the Dispensed Dose
The closure must release both phases in a usable and reasonably repeatable way after the defined shake step. Compare output, dripping, nozzle residue and dose-to-dose variation. If the first output after storage differs from later output, record it instead of hiding it in an edited demonstration.
A controlled-pour reducer or standard treatment pump may be considered after viscosity and remix behaviour are known. Pressurised or proprietary hardware adds a different sourcing and safety route and should not be assumed.
Decision 4: Treat Preservation as a Core Requirement
The formula contains water, so the preservation system and microbiological protection require qualified review. The FDA microbiological-safety overview identifies raw materials, water, manufacturing, ineffective preservation, packaging, storage and consumer use as possible contamination routes. That background does not prescribe a formula or certify a GUOCUI sample.
Do not call the product anhydrous because one layer is oil-rich. Ingredient documentation, manufacturing controls, package protection and the required finished-product evidence remain tied to the actual formula and destination market.
Decision 5: Approve the Filled Package
Review bottle material, closure, gasket, dip tube, headspace, leakage and orientation using the actual filled sample. Transparency can help the user see the phases, but light exposure may affect colour or formula condition. The FDA shelf-life overview notes that water-and-oil emulsions can separate and that temperature, sunlight, air and storage affect cosmetic condition. It does not supply a ready-made duration or test temperature.
Keep formula code, component code, fill quantity and carton orientation connected in the approval record. Empty-pack fit and a one-time leak check are incomplete evidence.
Decision 6: Separate Sensory Approval, Safety and Claims
A buyer may approve the spread and after-feel while the formula or evidence review remains open. Use separate approval fields for sensory feedback, phase behaviour, package performance, safety substantiation and label wording. The FDA product-testing page explains that manufacturers can use available safety information and may need further testing to fill gaps; natural origin alone does not establish safety.
Keep public wording within cosmetic body-care use after the required review. Avoid borrowed clinical figures, retinoid equivalence, universal multi-area suitability, guaranteed absorption or fixed hydration duration. A launch article is evidence that a product exists, not permission to transfer its evidence.
A Practical RFQ for the First Sample Round
Ask the buyer for the destination market, channel, intended body-use setting, finish, fragrance direction, ingredient restrictions, visibility preference, pack type, approximate capacity, label languages, quantity range and target timing. Request one preferred package and one acceptable standard alternative. The initial sample plan can compare two internally defined phase directions and record remixing, phase return, dose, residue and pack observations.
MOQ, quotation and production timing follow the selected formula, component, quantity, decoration, documentation, testing and shipping plan. The 5 September event supports a timely sourcing discussion; it does not justify invented urgency or a claim that the market has already adopted the format.
Frequently Asked Questions
Does the September launch prove demand for dual-phase body oil?
No. It verifies one dated product launch and product definition. Sell-through, review velocity and multi-channel growth were not established.
Why not add this direction to an existing body oil page?
The water-containing phase, defined remix step, preservation route and dose consistency create different filled-pack decisions from a conventional single-phase oil.
Should the two phases use an equal ratio?
Not by default. A buyer-owned ratio should follow the target feel, remix behaviour, preservation plan and dispenser results.
Can an attractive separation pattern count as stability evidence?
No. It is one visual observation. The actual formula and pack need the agreed stability, compatibility, safety and microbiological evidence.
What is the safest first commercial action?
Prepare a formula-and-package brief and a bounded sample comparison. Do not lock artwork, public claims or production terms before the filled-pack route is reviewed.
Sources and Next Step
- Churacos company release, 5 September 2026: confirms the dated launch, capacity and reference product’s phase structure.
- ULRUB official product page, read 8 September 2026: confirms the current exact product, shake instruction and full ingredient list.
- FDA microbiological-safety overview, read 8 September 2026: background for water, preservation, packaging and storage risks.
- FDA shelf-life overview, read 8 September 2026: background for separation and environmental exposure.
- FDA product-testing overview, read 8 September 2026: background for safety data and additional testing.
Compare the proposed Private Label Dual-Phase Body Serum-Oil with current post-shower body serum and single-phase cosmetic oil routes. Browse the Trend Center, Products and Customization, then send a dual-phase sample brief if the filled-pack questions match the project.
Leave a Reply